111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
支气管镜热蒸汽消融术治疗重度慢性阻塞性肺疾病患者的短期疗效：来自中国单中心的病例系列研究
Authors Kang BA, Zhang L, Duan X, Jiang B, Zhang YQ, Han JJ, Li HM
Received 23 July 2025
Accepted for publication 18 November 2025
Published 27 November 2025 Volume 2025:20 Pages 3819—3825
DOI https://doi.org/10.2147/COPD.S555654
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Vanesa Bellou
Bi-ang Kang,1,* Lei Zhang,2,* Xiaoying Duan,3,* Bo Jiang,2 Yi-Qian Zhang,2 Jing-Jun Han,2 Hua-Ming Li2
1Department of Cardiac Surgery, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic of China; 2Department of Thoracic Surgery, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, People’s Republic of China; 3Department of Emergency, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hua-Ming Li, Department of Thoracic Surgery, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518033, People’s Republic of China, Email lihm8@mail2.sysu.edu.cn
Background and Objective: Bronchoscopic Thermal Vapor Ablation (BTVA) is a novel endoscopic lung volume reduction (ELVR) technique designed to target emphysematous segments and reduce lung hyperinflation, especially in patients with heterogeneous emphysema. Although previous studies have demonstrated its efficacy in Western populations, data regarding BTVA outcomes in Asian cohorts remain limited. This study aimed to evaluate the short-term efficacy and safety of BTVA in patients with severe COPD in a real-world clinical setting.
Methods: This single-center, retrospective, observational study included 8 patients with advanced COPD who underwent BTVA at the Eighth Affiliated Hospital of Sun Yat-sen University between May 2023 and December 2024. Pulmonary function (FEV1, FVC, FEV1/FVC), 6-minute walk distance (6MWD), dyspnea scores (mMRC, CAT), and CT-based lung volume changes were assessed at baseline and at 1, 3, and 6 months post-treatment. Procedure-related adverse events were monitored for 1 month, and all patients were followed up for 6 months.
Results: All patients completed the 6-month follow-up. Significant improvements in FEV1, FVC, 6MWD, and clinical symptoms (CAT and mMRC) were observed as early as 1 month post-BTVA and were sustained through 6 months. Although FEV1/FVC showed no statistically significant change at 1 and 3 months, a significant increase was detected by month 6. CT imaging at 6 months revealed a marked reduction in the targeted lung volume from 707.5 ± 115.74 mL to 335.5 ± 129.59 mL. No severe adverse events were reported.
Conclusion: BTVA appears to be a safe and effective minimally invasive intervention for selected patients with advanced COPD, leading to significant short-term improvements in lung function, exercise capacity, and hyperinflation. These findings support the clinical utility of BTVA in Asian populations, although larger prospective studies are needed to confirm long-term benefits and assess repeatability.
Keywords: COPD, bronchoscopic thermal vapor ablation, emphysema, endoscopic lung volume reduction, interventional pulmonology
1Department of Cardiac Surgery, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic of China; 2Department of Thoracic Surgery, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, People’s Republic of China; 3Department of Emergency, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hua-Ming Li, Department of Thoracic Surgery, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518033, People’s Republic of China, Email lihm8@mail2.sysu.edu.cn
Background and Objective: Bronchoscopic Thermal Vapor Ablation (BTVA) is a novel endoscopic lung volume reduction (ELVR) technique designed to target emphysematous segments and reduce lung hyperinflation, especially in patients with heterogeneous emphysema. Although previous studies have demonstrated its efficacy in Western populations, data regarding BTVA outcomes in Asian cohorts remain limited. This study aimed to evaluate the short-term efficacy and safety of BTVA in patients with severe COPD in a real-world clinical setting.
Methods: This single-center, retrospective, observational study included 8 patients with advanced COPD who underwent BTVA at the Eighth Affiliated Hospital of Sun Yat-sen University between May 2023 and December 2024. Pulmonary function (FEV1, FVC, FEV1/FVC), 6-minute walk distance (6MWD), dyspnea scores (mMRC, CAT), and CT-based lung volume changes were assessed at baseline and at 1, 3, and 6 months post-treatment. Procedure-related adverse events were monitored for 1 month, and all patients were followed up for 6 months.
Results: All patients completed the 6-month follow-up. Significant improvements in FEV1, FVC, 6MWD, and clinical symptoms (CAT and mMRC) were observed as early as 1 month post-BTVA and were sustained through 6 months. Although FEV1/FVC showed no statistically significant change at 1 and 3 months, a significant increase was detected by month 6. CT imaging at 6 months revealed a marked reduction in the targeted lung volume from 707.5 ± 115.74 mL to 335.5 ± 129.59 mL. No severe adverse events were reported.
Conclusion: BTVA appears to be a safe and effective minimally invasive intervention for selected patients with advanced COPD, leading to significant short-term improvements in lung function, exercise capacity, and hyperinflation. These findings support the clinical utility of BTVA in Asian populations, although larger prospective studies are needed to confirm long-term benefits and assess repeatability.
Keywords: COPD, bronchoscopic thermal vapor ablation, emphysema, endoscopic lung volume reduction, interventional pulmonology